by Kazeem Olalekan MRPharmS My advise to patients requesting antibiotics for common cold will be: Stop; take a deep breath and count to 72 hours. There is now a well recognised problem of increasing antimicrobial resistance due to overuse (1). We all have a duty to do
Read more →
by Kazeem Olalekan In August of this year, bookapharmacist.com reported on the antimicrobial iphone app developed by the team at Southampton University Hospital NHS Trust (now: University Hospital Southampton NHS Foundation Trust). At the end of that piece, Kazeem promised to try and get an interview with
Read more →
by Kazeem Olalekan My last post: “Loose your tariff and your ethics“ has one too many “o” in it and was pointed out to me by my former student: Rahul Gogna on Facebook. That is the kind of attention to detail I expect from pharmacists especially some
Read more →
The news item yesterday on PJOnline which announced that preregistration trainees will not be requiring the Drug Tariff or Medicines, Ethics and Practice guide from next summer is encouraging. This is not to say that students should pay scant notice of issues relating to drug tariff and
Read more →
by Kazeem Olalekan I attended the Annual General Meeting of Hampshire and Isle of Wight LPC on the 14th of September 2011. The LPC has launched a new website (pictured) and after the paraphernalia of the AGM, it was time to introduce the key presenters: Professor John
Read more →
by Kazeem Olalekan MRPharmS When it comes to vision, I know what I will like mine to be like. Your visual acuity can be measured using a Snellen chart (pictured). A 20/20 vision means you can read the size 20 letters from a distance of 20
Read more →by Kazeem Olalekan MRPharmS Great video from the folks at Chemist and Druggist packed with suggestion for making the NMS service work for patients. I am currently embedding myself into the service and will undoubtedly unveil some nifty solution of my own in due course. Watch this
Read more →
**Limited spaces** The Wessex Pharmacy Forum, the local presence of the Royal Pharmaceutical Society is hosting a Conference on the 8th of October 2011 entitled: “The Indispensables!(?): Achieving a forward momentum through research and innovation”. Spaces are limited to 50 delegates only and it is going like
Read more →
by Kazeem Olalekan MRPharmS Can you spot the difference between these two tablet boxes. They look remarkably similar to me. Admittedly TEVA has done great work to make tablet boxes easily identifiable: An oversight perhaps? Patients beware.
Read more →
by Kazeem Olalekan MRPhamS At the recent Royal Pharmaceutical Society Conference, the strategy for supporting the future of pharmacy through education and professionalism was the theme of a break-out session. The following pieces of work are relevant: Defining professionalism (and its elements) in early career pharmacists R.
Read more →
by Kazeem Olalekan The discovery of blister packs of Seroquel XL (manufactured by AstraZeneca) and Neurontin 100mg capsules (manufactured by Pfizer) in Reckitt Benckiser’s Nurofen Plus OTC tablets is odder than odd (1)! As far as I can tell, these were not even manufactured in the same
Read more →
The MHRA has just posted a safety update that the use of pioglitazone is associated with a small increased risk of bladder cancer. Healthcare professionals should be aware of new warnings and precautions for use in at-risk patients. The advice for healthcare professionals include: Patients with active
Read more →
by Kazeem Olalekan MRPharmS The nation continues to face up to the aftermath of the riot that started in London and spread to different parts of the country. The perpetrators, the instigators and those just swept up in the whirlwind of mass behaviour are being identified and
Read more →
by Kazeem Olalekan MRPharmS I knew something was brewing at my hospital but wasn’t sure until I saw this headline in the Daily Echo: “Infection app is ‘sat nav for medicines’ (pictured). Then this headline on the PJ Online website: “Smartphone app aim to improve antimicrobial prescribing”
Read more →
